Biomimetic cancer cell membrane-enriched vitamin E-stapled gemcitabine-loaded TPGS micelles for pancreatic cancer therapy

Pancreatic cancer (PC) is currently a leading cause of death worldwide and its incidence is expected to increase in the following years. Chemotherapy with gemcitabine (GEM) is precluded by extensive enzymatic inactivation and clearance, and the nonspecific tissue distribution contributes to unwanted systemic toxicity and tumor resistance. In this work, GEM was encapsulated in d-ɑ-tocopheryl polyethylene glycol succinate (TPGS) micelles by ‘stapling’ GEM at 4-NH<sub>2</sub> position with vitamin E succinate (VES) through a highly stable amide bond, achieving successful GEM hydrophobization by means of a prodrug system (VES–GEM). Recurring to solvent evaporation methodology, TPGS/VES–GEM (6/1 molar ratio) micelles were prepared, optimized regarding TPGS-to-VES–GEM ratio, and characterized regarding size, surface charge, polydispersity index, morphology, drug loading, and encapsulation efficiency (EE). Furthermore, purification methods were explored together with VES–GEM release profile and stability. Lastly, cell viability and cellular uptake of the formulation were analyzed in 2D and 3D BxPC3 cell line models. TPGS/VES–GEM micelles (6/1) showed ultra-small size (∼30 nm), and remarkable EE (&gt;95%) together with ability to retain VES–GEM for long period of time (&gt;7 days) with high stability. The micelles demonstrated exceptional cell cytotoxic activity for concentrations of 10 and 100 µM VES–GEM (∼0% cell viability) which may be explained by concerted action of GEM, VES, and TPGS. The nanocarrier was further enriched with PC cell membrane nanovesicles, displaying size ∼150 nm, ZP ∼ −30 mV and PDI ∼0.2 to improve biointerfacing properties and targeting properties. BxPC3 cell membrane-modified TPGS/VES–GEM micelles may be attractive biomimetic nanosystem for next-generation PC therapeutics. Schematic illustration of the preparation of TPGS/VES–GEM, and BxPC3 cell membrane-coated TPGS/VES–GEM micelles for GEM delivery to PC cells.

Publication Details

Journal
Figshare
Published
2025-01-01
DOI
https://doi.org/10.6084/m9.figshare.29517472.v1
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biomimetic cancer cell membrane-enriched vitamin E-stapled gemcitabine-loaded TPGS micelles for pancreatic cancer therapy

Figshare
Nanoparticle-Based Drug Delivery
article

Biomimetic cancer cell membrane-enriched vitamin E-stapled gemcitabine-loaded TPGS micelles for pancreatic cancer therapy

article en

Abstract

Pancreatic cancer (PC) is currently a leading cause of death worldwide and its incidence is expected to increase in the following years. Chemotherapy with gemcitabine (GEM) is precluded by extensive enzymatic inactivation and clearance, and the nonspecific tissue distribution contributes to unwanted systemic toxicity and tumor resistance. In this work, GEM was encapsulated in d-ɑ-tocopheryl polyethylene glycol succinate (TPGS) micelles by ‘stapling’ GEM at 4-NH<sub>2</sub> position with vitamin E succinate (VES) through a highly stable amide bond, achieving successful GEM hydrophobization by means of a prodrug system (VES–GEM). Recurring to solvent evaporation methodology, TPGS/VES–GEM (6/1 molar ratio) micelles were prepared, optimized regarding TPGS-to-VES–GEM ratio, and characterized regarding size, surface charge, polydispersity index, morphology, drug loading, and encapsulation efficiency (EE). Furthermore, purification methods were explored together with VES–GEM release profile and stability. Lastly, cell viability and cellular uptake of the formulation were analyzed in 2D and 3D BxPC3 cell line models. TPGS/VES–GEM micelles (6/1) showed ultra-small size (∼30 nm), and remarkable EE (&gt;95%) together with ability to retain VES–GEM for long period of time (&gt;7 days) with high stability. The micelles demonstrated exceptional cell cytotoxic activity for concentrations of 10 and 100 µM VES–GEM (∼0% cell viability) which may be explained by concerted action of GEM, VES, and TPGS. The nanocarrier was further enriched with PC cell membrane nanovesicles, displaying size ∼150 nm, ZP ∼ −30 mV and PDI ∼0.2 to improve biointerfacing properties and targeting properties. BxPC3 cell membrane-modified TPGS/VES–GEM micelles may be attractive biomimetic nanosystem for next-generation PC therapeutics. Schematic illustration of the preparation of TPGS/VES–GEM, and BxPC3 cell membrane-coated TPGS/VES–GEM micelles for GEM delivery to PC cells.

Figshare
Good health and well-being
Openalex Percentile: Top 60%
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Biomimetic cancer cell membrane-enriched vitamin E-stapled gemcitabine-loaded TPGS micelles for pancreatic cancer therapy · Figshare (2025) | TGRS Research Map | TGRS